allogeneic myeloma vaccine
Vaccineexperimental
Clinical trial activity
2 trials · 2 clinical orgs · 0 marketing orgs
Phase 1
0
Phase 2
2
Phase 3
0
Phase 4
0
Earliest trial started Dec 1, 2009 (NCT01045460)
Timeline
2000s
- Jan 1, 2009
Earliest Phase 2 Sponsor(trial)
Indications
Studied for
Mechanism of action
- Tumor antigensImmunity, active
Tumor antigens immunity, active
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Also known as
- allogeneic myeloma vaccine
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT01349569 | Phase 2 | Jan 1, 2012 | Celgene, Johns Hopkins University |
| NCT01045460 | Phase 2 | Dec 1, 2009 | Johns Hopkins University |
Showing 2 of 2 trials
Page 1 / 1
Organizations
Research & Development (2)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Johns Hopkins University | Academic/Hospital | 2 | 2 | 1 | 2009 |
| Celgene | For profit | 1 | 0 | 1 | 2012 |
2 organizations
Page 1 / 1